Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07422688

Optical Coherence Tomography in Acute Vessel Evaluation

The purpose is to investigate if a strategy of routine OCT based diagnosis and guidance of PCI improves clinical outcomes compared with a standard strategy of guidance by angiography in patients presenting with ACS

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Leuven University Hospital, Leuven, Belgium

Loading trial locations.

About this study

Patients presenting with acute coronary syndrome (ACS) have worse short and mid-term prognosis compared with patients revascularized for chronic coronary syndrome. Angiographic assessment of patients with ACS is frequently limited by high ambiguity both in identification of culprit lesions, characterization of non-culprit lesions, and in identification of suboptimal treatment results. Intravascular imaging may improve diagnosis and allow for better treatment optimization during coronary intervention of patients with ACS. The large-scale Chinese IVUS-ACS trial showed a 50% reduction in one-year MACE with IVUS-guided PCI in patients with ACS whereas a number of small studies on routine OCT guiding as well as ACS subgroups in RCTs did not indicate a potential similar benefit with OCT. OCT assessment has several theoretical advantages over IVUS in patients with ACS indicating the need for a well-designed strategy trial on OCT vs angiographic guided PCI.

Hypothesis: Routine OCT-guided diagnosis and revascularization yields superior one-year clinical outcome compared with standard angiography-guided diagnosis and revascularization in patients with acute coronary syndrome Methods: Investigator initiated, open label, prospective, 1:1 randomized, multi-center, clinical outcome, superiority trial.

Primary Endpoint: Major adverse cardiac events (MACE) comprising all-cause death, spontaneous myocardial infarction and stroke.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical inclusion criteria:

  • NSTEMI, STEMI
  • Symptom duration <12h for STEMI and <48h for NSTEMI
  • Age ≥ 18yrs
  • Ability to provide written informed consent

Angiographic inclusion criteria:

  • Angiographic signs of at least one possible culprit lesion. Signs including acute occlusion, partial occlusion, proximal embolus, haziness, high grade stenosis, stent thrombosis
  • Wire in true distal lumen

Exclusion criteria

Clinical exclusion criteria

  • Intravascular imaging evaluation of any lesions at index procedure
  • Cardiogenic shock
  • Sustained ventricular tachycardia or ventricular fibrillation
  • Planned CABG
  • Life expectancy <1 year
  • Known severe heart failure with NYHA class equal or above III
  • Known ejection fraction <30% before the admission
  • Known renal failure with GFR <30 ml/min/1.73 m2
  • Active bleeding or coagulopathy
  • Relevant allergies (contrast media, aspirin, clopidogrel, ticagrelor, everolimus)
  • Suspected inability to lie flat for the duration of the PCI procedure
  • Inability to comply with the planned follow-up program
  • Known or anticipated compliance problems with medical therapy

Angiographic exclusion criteria

  • Study lesion involving the Left main coronary artery
  • Study lesion involving a true bifurcation lesion with a SB >2.5mm
  • Severe tortuosity
  • Distal embolus
  • Isolated coronary artery spasm
  • Suspected spontaneous coronary artery dissection
  • Chronic total occlusions with treatment indication and no antegrade intra plaque wire pass

Treatment and study plan

Angiographic Guided PCI

Procedure

Revascularization by percutaneous coronary intervention (PCI) guided by angiography alone

OCT Guided PCI

Procedure

Revascularization by percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)

Primary outcomes

  1. Combined endpoint of major adverse cardiac events (MACE)

    Time frame: 12 months

    Comprising all-cause death, spontaneous myocardial infarction and stroke

Secondary outcomes

  1. Combined endpoint of major adverse cardiac events (MACE)

    Time frame: 30 days, 36 months and 60 months

    Comprising all-cause death, spontaneous myocardial infarction and stroke

  2. Patient-oriented composite (PoCE) MACE endpoint

    Time frame: 30 days, 12 months, 36 months and 60 months

    Comprising all cause death, any myocardial infarction, any unplanned revascularization and stroke

  3. All-cause mortality

    Time frame: 30 days, 12 months, 36 months, 60 months and 10 years

    All-cause mortality includes death of any cause including cardiac deaths and non-natural causes of deaths

  4. Cardiac death

    Time frame: 30 days, 12 months, 36 months and 60 months

    Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death.

  5. Spontaneous myocardial infarction

    Time frame: 30 days, 12 months, 36 months and 60 months

    Following 4th universal MI definition

  6. Any ischemia-driven revascularization

    Time frame: 30 days, 12 months, 36 months and 60 months

    Any repeat iscemia-driven revascularization (coronary artery bypass grafting or PCI) except staged revascularization planned during the index procedure

  7. Any unplanned revascularization

    Time frame: 30 days, 12 months, 36 months and 60 months

    Any unplanned repeat revascularization

  8. Ischemia-driven target lesion revascularization

    Time frame: 30 days, 12 months, 36 months and 60 months

    Any non-staged repeat ischemia-driven revascularization (coronary artery bypass grafting or PCI) of any lesion treated at the index admission

  9. Ischemia-driven target vessel revascularization

    Time frame: 30 days, 12 months, 36 months and 60 months

    Any non-staged repeat ischemia-driven revascularization (coronary artery bypass grafting or PCI) of any vessel treated at the index admission

  10. Target lesion revascularization

    Time frame: 30 days, 12 months, 36 months and 60 months

    Any non-staged repeat revascularization (coronary artery bypass grafting or PCI) of any lesion treated at the index admission

  11. Target vessel revascularization

    Time frame: 30 days, 12 months, 36 months and 60 months

    Any non-staged repeat revascularization (coronary artery bypass grafting or PCI) of any vessel treated at the index admission

  12. Stroke

    Time frame: 30 days, 12 months, 36 months and 60 months

    Acute neurological deficit of cerebrovascular cause that persists beyond 24 hours with CT or MRI confirmation

  13. Rose dyspnea Scale

    Time frame: 30 days, 12 months, 36 months and 60 months

    Assesses the severity of dyspnea during specific physical activities, ranging from 0-4. Higher scores indicate worse dyspnea

  14. CCS-angina class

    Time frame: 30 days, 12 months, 36 months and 60 months

    4-level grading system to categorizes stable angina symptoms based on the severity of physical limitations

  15. Peri-procedure related MI

    Time frame: During or within 48 hours after the procedure (index or staged within the same admission)

    According to the ARC-2 and 4th universal definition criterias

  16. Stent thrombosis

    Time frame: 30 days, 12 months, 36 months and 60 months

    Definite, probable or possible in time categories: acute, subacute, late and very late (ARC-2 definitions)

  17. Contrast induced nephropathy

    Time frame: 48h

    Defined as a >50% increase in plasma creatinine after the procedure within the first 48 hours

Other outcomes

  1. Contrast volume

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    Total volume of contrast used at index admission

  2. Fluoroscopy time

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    Total fluoroscopy time during index admission

  3. Length of stents implanted in culprit lesion

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    Total length of stents implanted in culprit lesion

  4. Number of NCL treated

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    Number of Non Culprit Lesions treated

  5. Procedural failure

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    No stent implanted in target lesion

  6. Procedural success

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    TIMI III flow and less than 30% diameter stenosis in target segments by corelab QCA

  7. Procedure time

    Time frame: Baseline (index procedure and procedures staged within the same index admission)

    Total procedure time at index admission

Sponsors and collaborators

Lead sponsor

Aarhus University Hospital Skejby

Other

Collaborators

  • Abbott

Registry information

Official study title

Optical Coherence Tomography in Acute Vessel Evaluation (OCTAVE)

Acronym: OCTAVE

Important dates

Study start
2025
Primary completion
2030
Study completion
2039
First posted
Feb 20, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.